OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis → The Key to this $10 Trillion Tech Boom (From Porter & Company) (Ad) Free ANTH Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Anthera Pharmaceuticals alerts: Email Address Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Read More Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. ANTH Stock News HeadlinesJune 28, 2023 | finance.yahoo.comMACK - Merrimack Pharmaceuticals, Inc.May 16, 2023 | marketwatch.comIndustry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030May 16, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 5, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 4, 2023 | marketwatch.com2023-2030 Gaucher Disease Treatment Market Size (Growth and Outlook) includes Company Information | with [104 Pages]April 28, 2023 | marketwatch.comGaucher Disease Treatment Market Top Key Players by 2030April 7, 2023 | marketwatch.comGlobal Cystic Fibrosis Drugs Market Size 2023 to 2026 Size and Share Survey ReportMarch 28, 2023 | marketwatch.comCeliac Disease Drug Market Size and Forecast till 2030March 10, 2023 | marketwatch.comCystic Fibrosis Drugs Market 2023-2028 Recent Study by Trend and Growth AnalysisMarch 8, 2023 | finance.yahoo.comInfectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.February 26, 2023 | thestreet.comTwo Drugs, Designed To Help Patients, Actually Hurt ThemJanuary 13, 2023 | marketwatch.comGaucher Disease Treatment Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 7, 2023 | marketwatch.comCeliac Drugs Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028December 17, 2022 | marketwatch.comGaucher Disease Treatment Market Research report forecast 2023 To 2028, Latest Industry News, Top Company Analysis, Research MethodologyOctober 12, 2022 | marketwatch.comCystic Fibrosis Drugs Market 2022 | Upcoming Trends, Recent Development, Top Manufacturers, Industry Drivers and Forecast to 2028September 1, 2022 | apnews.comThryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of DirectorsAugust 26, 2022 | reuters.comANTH.PQ - Anthera Pharmaceuticals Inc | Stock Price & Latest News | ReutersJune 10, 2022 | benzinga.comAnthera Pharmaceuticals (OTC:ANTH), Short Interest ReportMay 10, 2022 | marketwatch.comVasculitis Treatment Market Size 2022 including Scope, Trends, Manufacturers, Growth Factors, Market Dynamics and Forecast to 2028April 21, 2022 | bizjournals.comThe Petri Dish: Two startups get new CEOs, workforce dev coalition ramps upApril 14, 2022 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Appoints Craig Thompson to the Board of DirectorsApril 13, 2022 | finance.yahoo.comNervGen Pharma Appoints Craig Thompson to the Board of DirectorsNovember 24, 2021 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD StudyOctober 26, 2021 | sg.finance.yahoo.comAnthera Pharmaceuticals, Inc. (ANTH)October 4, 2021 | marketwatch.comEPI Market 2021 : Global Industry Analysis, Trends, Market Size and Forecasts Up to 2025 with Dominant Sectors and Countries DataSee More Headlines Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2018Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ANTH CUSIPN/A CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.00 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul F. Truex M.B.A. (Age 55)Executive Chairman Comp: $100kMr. John Craig Thompson (Age 57)CEO & Director Comp: $715.3kMs. May Liu (Age 48)Senior VP of Finance & Administration and Principal Accounting Officer Comp: $373.44kDr. Paul Adams Ph.D. (Age 61)Senior Vice President of Global Regulatory Affairs and Compliance Joshua CaldwellChief Liquidating OfficerKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors ANTH Stock Analysis - Frequently Asked Questions How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Anthera Pharmaceuticals's stock reverse split on the morning of Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), Amicus Therapeutics (FOLD) and Alibaba Group (BABA). How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ANTH) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredMillions of Unsuspecting Americans Could be Wiped Out…America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economi...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anthera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.